Guo, J.; Lewis, K.A.; Prakash, L.; Bhosale, P.; Morani, A.; Katz, M.H.G.; Tzeng, C.-W.D.; Ikoma, N.; Snyder, R.; Kim, M.P.;
et al. Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor. Curr. Oncol. 2026, 33, 111.
https://doi.org/10.3390/curroncol33020111
AMA Style
Guo J, Lewis KA, Prakash L, Bhosale P, Morani A, Katz MHG, Tzeng C-WD, Ikoma N, Snyder R, Kim MP,
et al. Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor. Current Oncology. 2026; 33(2):111.
https://doi.org/10.3390/curroncol33020111
Chicago/Turabian Style
Guo, Jin, Kever A. Lewis, Laura Prakash, Priya Bhosale, Ajaykumar Morani, Matthew H. G. Katz, Ching-Wei D. Tzeng, Naruhiko Ikoma, Rebecca Snyder, Michael P. Kim,
and et al. 2026. "Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor" Current Oncology 33, no. 2: 111.
https://doi.org/10.3390/curroncol33020111
APA Style
Guo, J., Lewis, K. A., Prakash, L., Bhosale, P., Morani, A., Katz, M. H. G., Tzeng, C.-W. D., Ikoma, N., Snyder, R., Kim, M. P., Chandrasekharan, C., Dasari, A., Yao, J. C., Lee, J. E., Maxwell, J. E., & Halperin, D. M.
(2026). Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor. Current Oncology, 33(2), 111.
https://doi.org/10.3390/curroncol33020111
